Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 30 November 2017, 08:41 HKT/SGT
Share:
    

Source: Eisai
Eisai's Resubmitted NDA for Anticancer Agent Halaven Accepted in China

TOKYO, Nov 30, 2017 - (JCN Newswire) - Eisai Co., Ltd. announced today that the China Food and Drug Administration (CFDA) has accepted for review the resubmitted New Drug Application (NDA) for Eisai's anticancer agent eribulin mesylate (eribulin, product name: Halaven).

In July 2016, Eisai submitted an NDA for eribulin for use in the treatment of locally advanced or metastatic breast cancer in China. However, in alignment with Chinese regulations, Eisai temporarily withdrew its application in June 2017 in order to submit additional documentation. The application was resubmitted once preparations of additional documentation were completed.

Eisai positions oncology as a key therapeutic area, and is aiming to discovery revolutionary new medicines with the potential to cure cancer. Eisai remains committed to maximizing the clinical value as well as exploring the potential clinical benefits of Halaven as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers in China and around the world.


About Eisai

Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.

Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120


Nov 30, 2017 08:41 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2018 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Jan 11, 2018 10:46 HKT/SGT
Eisai Completes Construction of Oral Solid Dose Production Facility at New Suzhou Plant in China
Jan 9, 2018 20:24 HKT/SGT
Biogen and Eisai Commence Co-Promotion of Multiple Sclerosis Treatments in Japan
Jan 9, 2018 20:02 HKT/SGT
Eisai and Merck & Co. Receive Breakthrough Therapy Designation from U.S. FDA for LENVIMA and KEYTRUDA
Dec 27, 2017 09:42 HKT/SGT
Eisai: Anticancer Agent Lenvatinib Designated for Priority Review and Approval by CFDA for Hepatocellular Carcinoma
Dec 22, 2017 10:22 HKT/SGT
Eisai: Adaptive Phase II Study of BAN2401 In Early Alzheimer's Disease Continues Toward 18-Month Endpoint
Dec 18, 2017 13:40 HKT/SGT
Eisai Launches Educational Materials for Understanding Dementia
Dec 13, 2017 15:59 HKT/SGT
Eisai's Aricept Approved for Additional Indication of Severe Alzheimer's Disease in China
Dec 8, 2017 13:57 HKT/SGT
Eisai: Updated Analysis of Phase Ib/II Study of Eribulin and Pembrolizumab Combination Regimen
Dec 6, 2017 16:31 HKT/SGT
Eisai Submits Application for Expanded Indication Covering Hepatocellular Carcinoma for Anticancer Agent Lenvima in Taiwan
Nov 24, 2017 14:07 HKT/SGT
Eisai to Present Latest Data on Perampanel and Rufinamide at 71st American Epilepsy Society Annual Meeting
More news >>
 News Alerts
Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: